Ind-Swift Laboratories Ltd.
NSE: INDSWFTLAB · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
1,209cr
P/E
4.9
ROE
25.5%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Ind-Swift Laboratories Ltd. | 17.0% | 24.8% |
What management said
19 statements on recordEarnings call · Q1 FY27 · 20 Aug 2026
- CDMO partnerships incremental revenue→₹200 to ₹220 crore· FY27
“These are expected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27, and represent a key milestone in scaling our contract manufacturing business with global generic majors.”
- Viatris two products revenue→₹100-130 odd crores· year one
“Yes, we are expecting approx. ₹100-130 odd crores in these two products. Not the entire ₹200 crores in year one. Gradually it will increase.”
- CDMO partnership revenue ramp-up→₹200 crores· period of two years
“It will be in a period of two years.”
- EBITDA margin→minimum 18 to 20% EBITDA margins
“We were saying this to lot of investors that minimum 18 to 20% EBITDA margins are there in this business and now it has been clearly depicted.”
- EBITDA margin sustainability / upside→18% fully sustainable; may go up to 21 to 22%
“Yes, yes, 18% is fully sustainable and we plan if the sales we are able to increase quarter-on-quarter they might go up to 21 to 22%.”
- Capex deployment→₹250 crores· 2.5 years approx.
“So that ₹250 crores will be deployed in capex over a period of 2.5 years approx.”
- Revenue→minimum ₹1500 crores of a revenue· FY30
“FY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.”
- Net profit→approx ₹200 plus· FY30
“FY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.”
- Incremental CDMO revenue from two opportunities→approx ₹150 crores in totality
“The two opportunities which we got a couple of years back would give us an incremental revenue of approx ₹150 crores in totality.”
- Export sales→around ₹750 crores· this year
“And about the numbers, we should do export sales of around ₹750 crores and 45% of this should be the CDMO business.”
- CDMO share of export sales→approx. 45%· this year
“The total export sales which we are expecting this year is ₹750 crores. And out of ₹750 crores, approx. 45% would be through the CDMO business.”
- CDMO revenue within FY29 revenue→₹600 to 650 crores of CDMO· FY29
“So this is part of that FY29; should we assume that FY29 ₹1200 crores will have, say ₹600 to 650 crores of CDMO? Is that the way to look at? Gagan Aggarwal: Yes.”
- Capacity utilisation→90% of capacity· till FY29
“See, we are gradually increasing our capacities every day. So the plan which we have given till FY29 should be the 90% of capacity which will be used over a period of time.”
- Dossiers target→from 2100 to 2500· Q4 of this year
“We should be 400 plus. So from 2100 to 2500 is where we will reach by Q4 of this year.”
- Revenue growth CAGR→20 to 25% of CAGR· medium term / beyond FY27
“Mohit Jangir: Okay. And sir, going by your guidance in the presentation, so we are targeting 20 to 25% of CAGR in the medium term. So beyond FY27, can we expect this kind of growth rate with EBITDA margins above 18%? Gagan Aggarwal: Yes.”
- Revenue→900 crores· this year
“See we are expecting sir 900 crores this year.”
- New customer capex and revenue→capex ₹50 to 75 crores; revenue 150 plus
“See, the capex should be between the tune of ₹50 to 75 crores. And the revenue should be 150 plus.”
- Capex→₹250 crores· two years' time
“₹250 crores is the capex which we'll spend over a period of two years' time.”
- Viatris product volumes→double than what we did in the first quarter· second quarter
“The product has been well accepted by them and in this in this second quarter we expect these volumes to grow double than what we did in the first quarter.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
No broadcast calls recorded.
We log calls made about a company on business television — Zee Business, CNBC Awaaz and NDTV Profit — as they are stated on air. Nothing is on record for Ind-Swift Laboratories Ltd..
Shareholding
change across 4 filings| Category | Sep 26 | Jun 26 | Mar 26 | Feb 26 | Change |
|---|---|---|---|---|---|
| Promoters | 42.9 | 42.9 | 43.0 | 43.1 | −0.2 |
| Foreign institutions | 10.9 | 10.7 | 13.9 | 13.8 | −2.9 |
| Domestic institutions | 0.2 | 0.2 | 0.0 | 0.2 | 0.0 |
| Retail & others | 46.0 | 46.2 | 43.1 | 43.0 | +3.0 |
As filed with the exchange for the periods ending Feb 26 to Sep 26.
Filings
latest 25 of 239- General Updates12 Oct 2026
- Conversion8 Oct 2026
- Copy of Newspaper Publication6 Oct 2026
- Shareholders meeting5 Oct 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20185 Oct 2026
- Shareholders meeting30 Sept 2026
- General Updates28 Sept 2026
- Trading Window28 Sept 2026
- Please find enclosed Schedule of Analyst / Investor Meet scheduled to be held on Tuesday, 29th September, 2026, at 01.00 P.M. IST23 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates23 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd & Others22 Sept 2026
- Please refer attached pdf.21 Sept 2026
- General Updates21 Sept 2026
- Outcome of Preferential Issue Committee for Allotment of 70,00,000 Fully Convertible Warrants on Preferential Basis17 Sept 2026
- Allotment of Securities17 Sept 2026
- Copy of Newspaper Publication4 Sept 2026
- Please refer attached newspaper publication dated 04.09.2026.4 Sept 2026
- General Updates4 Sept 2026
- Please refer attached pdf.4 Sept 2026
- Outcome of Board Meeting2 Sept 2026
- Please find enclosed outcome of Board Meeting held on September 02, 2026.2 Sept 2026
- Spurt in Volume28 Aug 2026
- General Updates27 Aug 2026
- Please refer attached pdf regarding clarification sought from company regarding movement in value .27 Aug 2026
- The Exchange has sought clarification from Ind-Swift Laboratories Ltd on August 27, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.27 Aug 2026RoutineGeneral
The 25 most recent of 239 filings we hold for INDSWFTLAB, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.